End-of-day quote
Korea S.E.
03:30:00 14/05/2024 am IST
5-day change
1st Jan Change
33,850
KRW
0.00%
-2.87%
-11.85%
LIPAC Oncology and Huons Co. Announces Exclusive Licensing Agreement for TSD-001 in Korea
September 16, 2019 at 06:30 pm IST
LIPAC Oncology LLC and Huons Co., Ltd. announced that they have entered into an exclusive licensing agreement to develop, manufacture and commercialize TSD-001 for all indications in Korea. Huons is making an upfront payment and future milestone payments to LIPAC based on specific development, regulatory and commercial milestones. Huons will also make double-digit royalty payments based on sales. TSD-001 is a proliposomal intravesical paclitaxel formulation (PLIP), currently in development for intravesical administration in the treatment of non-muscle invasive bladder cancer (NMIBC). NMIBC is a common and highly recurrent disease that can often be difficult to treat. If approved, TSD-001 would be the first chemotherapeutic agent approved by the U.S. Food and Drug Administration for this indication in almost two decades. Additional indications covered by the agreement include upper tract urothelial carcinoma, stage II/III ovarian cancer and peritoneal carcinoma.
PanGen Biotech Inc. announced that it has received KRW 3.999986631 billion in funding from CrystalGenomics Invites Co., LTD., Huons Co., Ltd., Hwail Pharmaceutical Co.,Ltd.
27/03
CI
Huons Co., Ltd. Reports Earnings Results for the Full Year Ended December 31, 2023
20/03
CI
PanGen Biotech Inc. announced that it expects to receive KRW 3.999986631 billion in funding from CrystalGenomics Invites Co., LTD., Huons Co., Ltd., Hwail Pharmaceutical Co.,Ltd.
18/03
CI
GenEdit Inc. announced that it has received $24 million in funding from Korea Innovative Medicines Consortium, Dong-A ST Co., Ltd., Huons Co., Ltd.
24/01
CI
Huons Co., Ltd. Reports Earnings Results for the Full Year Ended December 31, 2022
23/23/23
CI
South Korea's Huons to Export Anesthetics to Canada
01/23/01
MT
GenEdit Inc. amended terms of the transaction
28/23/28
CI
South Korean Stocks Turn Upbeat as China COVID-19 Lockdown Restrictions Ease; Huons Adds 1%
29/22/29
MT
Huons to Invest $18.3 Million to Raise Production Capacity for Injectable Products at Jecheon Plant
29/22/29
MT
GenEdit Inc. announced that it expects to receive $30 million in funding
09/22/09
CI
Haemato : to Seek EU Approval for Botox Product
25/21/25
MT
PanGen Biotech Inc. announced that it has received KRW 9.99998571 billion in funding from Huons Co., Ltd. and another investor
11/21/11
CI
PanGen Biotech Inc. announced that it expects to receive KRW 9.99998571 billion in funding from Huons Co., Ltd., and another investor
03/21/03
CI
Pharmcadd Co, Ltd announced that it has received $16 million in funding from a group of investors
19/21/19
CI
Master Meditech Inc. announced that it has received KRW 8 billion in funding from Samho Green Investment, Inc., Paratus Investment Inc., Spring Camp, Huons Co., Ltd., Pharmbio Co., Ltd., INNOCENCE Co.Ltd
29/21/29
CI
Tranche Update on Huons Co., Ltd.'s Equity Buyback Plan announced on August 14, 2020.
23/21/23
CI
Tranche Update on Huons Co., Ltd.'s Equity Buyback Plan announced on August 14, 2020.
23/21/23
CI
Huons Co., Ltd.'s Equity Buyback announced on August 14, 2020, has expired with 80,102 shares, representing 0.74% for KRW 4,989.56 million.
18/21/18
CI
LIPAC Oncology Announces Major Partnering Milestone Achieved in Its License Agreement with Huons Co., Ltd
10/20/10
CI
Tranche Update on Huons Co., Ltd.'s Equity Buyback Plan announced on August 14, 2020.
23/20/23
CI
Huons Co., Ltd. announced that it has received KRW 50 billion in funding from a group of investors
13/20/13
CI
Huons Co., Ltd. announced that it expects to receive KRW 50 billion in funding from a group of investors
11/20/11
CI
Huons Co., Ltd. announces an Equity Buyback for KRW 5,000 million worth of its shares.
14/20/14
CI
Huons Co., Ltd. authorizes a Buyback Plan.
14/20/14
CI
LIPAC Oncology and Huons Co. Announces Exclusive Licensing Agreement for TSD-001 in Korea
16/19/16
CI
Duration Auto. 2 months 3 months 6 months 9 months 1 year 2 years 5 years 10 years Max.
Period Day Week
More charts
Huons Co., Ltd. is a Korea-based company principally engaged in manufacture of general medicine and special medicine.
More about the company
Last Close Price
33,850
KRW
Average target price
54,000
KRW
Spread / Average Target
+59.53%
Consensus
1st Jan change
Capi.
-11.85% 295M +31.37% 588B -2.60% 364B +20.83% 326B +5.69% 285B +14.83% 239B +9.93% 210B -6.95% 200B +10.77% 167B +0.10% 161B
Other Pharmaceuticals
+951% of historical performance
More than 20 years at your side
Our Experts are here for you
OUR EXPERTS ARE HERE FOR YOU
Monday - Friday 9am-12pm / 2pm-6pm GMT + 1